IMPEDIMED LIMITED — AGM Information 2021

Nov 9, 2021

==> picture [230 x 54] intentionally omitted <==

10 November 2021

ASX ANNOUNCEMENT

2021 Annual General Meeting – CEO’s Presentation

ImpediMed Limited ( ImpediMed ) (ASX: IPD) provides the attached CEO’s presentation to be delivered at today’s Annual General Meeting commencing at 9.00am AEDT.

The webcast of the AGM can be joined at: www.agmlive.link/IPD21.

Authorised for release by Mr Richard Carreon, Managing Director and Chief Executive Officer of ImpediMed Limited.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: https://www.impedimed.com/products/sozo/.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

AGM PRESENTATION

NOVEMBER 2021

SOZO[®] Digital Health Platform

ü Technology

ü Transformation

ü Adoption ü Affirmation Growth

==> picture [851 x 199] intentionally omitted <==

==> picture [395 x 92] intentionally omitted <==

Disclaimer

• The material contained in this document is a presentation of general information about the activities of ImpediMed Limited (“ImpediMed”) current as at the date of this presentation. The information is provided in a summary form, does not purport to be complete and should not be relied as advice for investment This does not take into upon purposes. presentation

• account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

• SOZO[®] is intended only for use in countries in which it has received regulatory approval or clearance. Inclusion of products and information does not imply any official medical advice, recommendation or warranty. The information provided is not a substitute for the advice of an appropriate health professional. ImpediMed’s website can be accessed from countries around the world and may contain references to products that have not been granted regulatory approval or clearance in your country. You should consult your health professional for detailed information regarding ImpediMed’s products and their suitability for you, as well as the regulatory approval or clearance status of such products in your country.

• To the extent permitted by law, no responsibility for any loss arising in any way (including by of from or to act as a result of this or

• way negligence) anyone acting refraining presentation its contents is accepted by ImpediMed or any of its officers, employees or agents.

• The information in this presentation is subject to change and unless required by law, ImpediMed assumes no obligation to update this presentation or its contents for any matter arising or coming to ImpediMed’s notice after the date of this presentation.

Forward Looking Statements

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs. The forward-looking statements in this release include statements regarding the next generation product, the ability of the new features to broaden the appeal of the product, and the ability of new product to meet the needs of the customer base, among others. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results may differ materially from what is expressed in this presentation.

There can be no assurance that or future will the any existing regulatory filings satisfy relevant authorities’ requirements regarding SOZO nor can there be any assurance that SOZO will be approved or cleared for all applications by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding ImpediMed’s ability to commercialise SOZO, including its estimates of potential revenues, costs, profitability and financial performance could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; its ability to maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

==> picture [361 x 83] intentionally omitted <==

Our Transformation

Connected Di ital Health Platform g

Medical Device

SOZO Platform

U400 BIS Device U400 Cancer Population[^]

==> picture [83 x 589] intentionally omitted <==

SOZO[®]

Cancer Population[^]

==> picture [372 x 370] intentionally omitted <==

==> picture [349 x 349] intentionally omitted <==

• Less than 30 Second Test

• ~20 Minute Test

• Medical Assistant

• Trained Nurse/Therapist

• Connected Device

• Standalone Device

• Cloud-based SaaS* Pricing Model

• Gel Backed Electrodes

• On Device, Online or via EHR**

• Manual Data Download

• Multiple Applications

• Single Application

==> picture [287 x 470] intentionally omitted <==

==> picture [639 x 214] intentionally omitted <==

• SaaS = Software-as-a-Service ** EHR = Electronic Health Records ^ The bubbles depicting Cancer Population sizes are for illustrative purposes only and not reflective of actual market sizes. 1. Bone analysis and FDA clearance is in development.

==> picture [1920 x 50] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 3
----- End of picture text -----

==> picture [361 x 83] intentionally omitted <==

Comprehensive Data

SOZO[®] measures and tracks critical patient data

• L-Dex[®] lymphoedema index

• Total body water

• Extracellular fluid

• Intracellular fluid

• Skeletal muscle mass

• Fat mass

• Fat-free mass

• HF-Dex[TM] heart failure index

• Protein and minerals

• • Basal metabolic rate

• • Phase angle

• • Body mass index

• Segmental analysis

• • Hy-Dex[®] hydration analysis[1]

==> picture [1920 x 50] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 4
----- End of picture text -----

1. Hy-Dex[®] hydration analysis is only intended for use with healthy individuals.

Connected Digital Health Platform Test patients at any location and allows data access and sharing across the entire healthcare system

==> picture [186 x 34] intentionally omitted <==

==> picture [358 x 349] intentionally omitted <==

----- Start of picture text -----

Access
Test patients at any location
and immediately review
results online
Trends
Track trends in patient data
for actionable results
----- End of picture text -----

==> picture [979 x 592] intentionally omitted <==

----- Start of picture text -----

Cloud
Scalable
Add and move test locations
without any additional software
setup
Secure
Control who accesses the
SOZO network and establish
unique security settings
----- End of picture text -----

==> picture [128 x 96] intentionally omitted <==

==> picture [107 x 54] intentionally omitted <==

==> picture [124 x 74] intentionally omitted <==

==> picture [1920 x 50] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 56
----- End of picture text -----

==> picture [395 x 92] intentionally omitted <==

==> picture [1069 x 828] intentionally omitted <==

SOZO[®] Digital Health Platform

==> picture [497 x 736] intentionally omitted <==

----- Start of picture text -----

1 Device, Multiple Applications
Lymphoedema
FDA Clearance, CE Mark
Heart Failure
FDA Clearance, CE Mark
End Stage Renal Disease
CE Mark
Protein Calorie Malnutrition
FDA Clearance, CE Mark
Body Composition
FDA Clearance, CE Mark
^
Bone Density
^^
Venous Insufficiency
----- End of picture text -----*

• kidneyfund.org: Kidney failure is the last and most severe stage of chronic kidney disease and is also referred to as End-Stage Renal Disease (ESRD) ^ Algorithm has been developed and preliminary discussions have been held with FDA ^^ Proof of concept studies undertaken; no regulatory applications submitted to date

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 6
----- End of picture text -----

==> picture [395 x 92] intentionally omitted <==

• Platform Technology: Initial Focus on Three Large Overlapping Markets

Critical is the ability to accurately measure small shifts in fluid and tissue

$2.0+ Billion Annual Addressable Market

• Cardiovascular disease is the leading cause of death among people on dialysis with kidney disease

• Dialysis patients experience high rates of mortality, driven largely by an exceptionally high rate of cardiovascular related mortality

• Common for people with chronic kidney disease or end stage renal failure to develop heart disease

• Heart failure leads to a 11.4x greater risk for end stage renal failure

• Protein calorie malnutrition or protein energy wasting is common in patients with chronic kidney disease and is one of the strongest predictors of patient mortality

• Cardiovascular disease is the predominant cause of death in breast cancer patients aged over 50

• The risk of death from heart disease in cancer patients is 2.24x that of the general population

• Protein calorie malnutrition is the most common secondary

• diagnosis in cancer patients affecting more than 50% of patients with certain cancers

Oncology Heart Failure Lymphoedema Fluid Overload Protein Calorie Malnutrition^ Protein Calorie Malnutrition^ A$1+ billion A$700+ million Renal Failure Fluid Overload Protein Energy Wasting^ A$300+ million

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 7
----- End of picture text -----

Strong Adoption, Validated Technology 810+ 410+ SOZO Devices in SOZO Devices in Core Business Clinical Business 35 2 international drug studies involving 410+ sites in 28 countries evaluating fluid volumes (heart failure & renal failure patients)

==> picture [253 x 90] intentionally omitted <==

==> picture [262 x 81] intentionally omitted <==

==> picture [186 x 87] intentionally omitted <==

==> picture [232 x 164] intentionally omitted <==

==> picture [227 x 126] intentionally omitted <==

==> picture [276 x 105] intentionally omitted <==

8

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed.

==> picture [361 x 83] intentionally omitted <==

Summary of Achievements Since Last AGM

Total Revenue of $8.4 million in FY21, an increase of 46% year-over-year, which resulted in a $10 million Annual Run Rate based on Q4 FY’21 revenue. Business now fully funded: Completed a $35 million Placement to new and existing institutional and sophisticated investors, increasing the pro forma cash balance to approximately $48 million, net of fees, which gives the Company sufficient capital to achieve breakeven while still allowing for investment in key growth initiatives. Additional $5 million Share Purchase Plan (SPP) open through 11 November 2021 for eligible shareholders. Achieved HITRUST Certification and released next generation Version 4.0 software for the SOZO[®] Digital Health Platform, which contained a series of significant enhancements around usability, new applications, and security.

PREVENT Trial results released; trial met primary end point and reached statistical and clinical significance.

Meta-analysis published, demonstrating a statistically significant reduction in lymphoedema.

• Landmark radiation manuscript published, a sub-analysis of the PREVENT trial that demonstrates the benefit of BIS L-Dex in detecting subclinical breast cancer-related lymphoedema (sBCRL) compared to tape measure.

• Continued to advance private payor coverage/payment for L-Dex[®] testing, including Case Assistance Program, Medicare Advantage and Payor Advisory Board.

• SOZO Heart Failure program initiated at Advocate Health Care’s Heart Institute, which is part of AdvocateAurora Health. Advocate is a key heart failure centre for piloting the clinical and commercial applicability of SOZO and reimbursement. The Advocate Heart Institute has over 100 sites, where 350 specialists perform more than 20,000 heart procedures each year.

• US FDA 510(k) clearance for SOZO expanded to include a heart failure index (HF-Dex[TM] ) as a monitoring tool for patients living with heart failure.

• Heart Failure data demonstrating the potential of SOZO in Heart Failure: (i) Abstracts presented at the HFSA Annual Scientific Meeting in September 2021, (ii) published American College of Cardiology (ACC) abstract, and (iii) published peer-reviewed manuscript demonstrating the clinical utility of ImpediMed’s SOZO device in monitoring heart failure patients in Frontiers in Cardiovascular Medicine.

• AstraZeneca selected SOZO for two large Phase II trials to measure fluid volume in patients with heart failure and chronic kidney disease. 375 SOZO devices are being leased across 28 countries.

• AstraZeneca trial extended and expanded, resulting in over 410 SOZO devices being leased across the ongoing AstraZeneca trials. In total, the contracts are expected to generate over $5.0 million in revenue across the trials.

• SOZO received FDA Breakthrough Device Designation for a proposed indication in a renal patient population. The breakthrough designation positions ImpediMed to successfully expand its SOZO platform into the renal space. ImpediMed will partner with the FDA to expediate the development and clearance of SOZO. The breakthrough sprint sessions are the perfect forum to develop the clinical evidence plan, including trial design, to obtain data that will result in a successful clearance to market.

==> picture [1920 x 50] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 9
----- End of picture text -----

2021 Financial Year Results

==> picture [361 x 83] intentionally omitted <==

==> picture [1780 x 793] intentionally omitted <==

----- Start of picture text -----

SOZO Revenue Patient Tests To-Date
(Excluding Legacy) (261,000+ on File)
$8.4m
$10m+ $8,000,000 130,000
Total Revenue
Annual Revenue
+46% YOY
Run Rate
✓ RECORD YEAR
$6,000,000 97,500
90%+ SaaS
Gross Margins
$7.6m
$12m+
SOZO Revenue
Total Contract Value $4,000,000 65,000
+64% YOY
signed in FY’21
✓ RECORD YEAR
$2,000,000 32,500
$48m+ 127,000+
Cash Balance^^ SOZO Patient Tests
COVID-19 COVID-19
+60% YOY $- '-
✓ RECORD YEAR
SaaS^ Device and Contract Fees Patient Tests
FY'17 FY'18 FY'19 FY'20 FY'21 FY'17 FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

^The values shown are for SaaS Revenue are across all lines of business, including the Core Business and Clinical Business. The Company began breaking out revenue from the Clinical Business in Q1 FY’21.

^^ Cash balance based on pro forma cash (i) including the Placement proceeds, (ii) net of anticipated Capital Raising costs, and (iii) prior to the results of the Share Placement Plan as at 30 September 2021.

All figures are stated in Australian dollars (AUD) unless otherwise notated.

10

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed.

==> picture [361 x 83] intentionally omitted <==

Inflection point with identifiable growth drivers

• Transformation to Connected Digital Health Platform complete

• $10m annual revenue run rate with strong growth despite COVID-19 headwinds

• Multiple applications addressing significant health care needs

==> picture [667 x 608] intentionally omitted <==

• ~$48m in cash after capital raising[^]

• Company at an inflection point, with 3 focus areas set to accelerate adoption: 1. PREVENT driving Lymphoedema and Oncology adoption 2. Heart Failure commercialisation underway 3. Renal Failure accelerated with breakthrough designation

^Cash balance based on pro forma cash (i) including the Placement proceeds, (ii) net of anticipated Capital Raising costs, and (ii) prior to the results of the Share Placement Plan as at 30 September 2021.

All FY’22 revenue and cash flow numbers are unaudited. All figures are stated in Australian dollars (AUD) unless otherwise notated.

==> picture [1920 x 50] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 11
----- End of picture text -----

==> picture [361 x 83] intentionally omitted <==

PREVENT driving Lymphoedema and Oncology adoption

PREVENT Trial Successful, Statistically Significant

Consistent Reduction in Lymphoedema Progression Study after Study

• PREVENT trial showed 92% of patients with early detection of cancerrelated lymphoedema using L-Dex and intervention did not progress to chronic lymphoedema

• Met primary end point, demonstrating statistical and clinical significance

• Results demonstrate that BIS screening should be a standard approach for prospective breast cancer-related lymphoedema (BCRL) surveillance

• In patients with early detection using L-Dex, intervention resulted in a 7.9% rate of chronic lymphoedema compared to a 19.2% rate of chronic lymphoedema in patients with early detection using tape measure (p=0.016)

• This statistically significant level I evidence study is key to reimbursement and establishing L-Dex as standard of care

• PREVENT results available on medRxiv.org

==> picture [897 x 495] intentionally omitted <==

• Peer-review publication expected in coming months

==> picture [612 x 24] intentionally omitted <==

----- Start of picture text -----

Out of 89 patients, 82 avoided chronic lymphoedema
----- End of picture text -----*

PREVENT Trial: Ridner SH, et al. A Randomized Clinical Trial of Bioimpedance Spectroscopy or Tape Measurement Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. medRxiv.org 2021; https://www.medrxiv.org/content/10.1101/2021.10.12.21264773v1. Breast Care Specialists: Kaufman DI, et al. Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema. Breast Can Res Treat. 2017;DOI 10.1007/s10549-017-4451-x. Macquarie University: Koelmeyer LA, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. Cancer 2018;DOI: 10.1002/cncr.31873. Nashville Breast Center: Whitworth PW and Cooper A. Reducing chronic breast cancer-related lymphedema utilizing a program of prospective surveillance with bioimpedance spectroscopy. Breast J. 2017;1-4. Texas Breast Specialists: Laidley A and Anglin B. The impact of L-Dex measurements in assessing breast cancer-related lymphedema as part of routine clinical practice. Frontiers in Oncology 2016;6(192). University of Kansas: Kilgore L, at al. Reducing breast cancer-related lymphedema (BCRL) through prospective surveillance monitoring using bioimpedance spectroscopy (BIS) and patient direction self-interventions. Ann Surg Oncol 2018;http://doi.org/10.1245/s10434-018-6601-8. UPMC: Soran A, et al. The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection; a prospective observational study. Lymph Res Bio. 2014;12(4):289-94.

12

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed.

==> picture [395 x 92] intentionally omitted <==

Growth Drivers: Reimbursement & NCCN Guidelines[®]

NCCN[®]

Reimbursement

• NCCN Submission upon PREVENT publication

• PREVENT randomised control trial the key to reimbursement and accelerating growth

• Current NCCN submission covering the Meta-Analysis and Radiation Paper data is being evaluated

• PREVENT delivers clear path to reimbursement

• Current Guidelines

• IPD Case Assistance Program:

• Lymphoedema is a potential side effect after surgery

• Won over 400 cases with commercial payors to date

• Early detection is key for optimal management

• Over 100 cases won in last month alone

• Consider pre-treatment baseline measurements

• Equates to 97%+ of all cases won to date with target payors

• Majority of clinicians still using tape measure to comply

• 1,300+ active cases

  • Meta-Analysis and the Radiation Paper data show volumetric measurements, such as tape measure, aren’t as effective as ImpediMed’s BIS L-Dex[®] measurements

• Standard Medicare rate:

• USD $143 per SOZO[®] test

  • PREVENT removes any sense of ambiguity regarding the comparison of BIS to a tape measure. Statistically and clinically significant evidence that BIS makes an important contribution in preventing lymphoedema

• Facilities are receiving increased payments through recently obtained Medicare Advantage:

• USD $174 - $222 per SOZO[®] test

• BIS L-Dex being specified in NCCN Guidelines would significantly accelerate adoption

• Payor advisory board to convene in the coming weeks to chart path forward

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 13
----- End of picture text -----

==> picture [395 x 92] intentionally omitted <==

Heart Failure Commercialisation Underway

SOZO[®] Heart Failure Patient Output

• Heart Failure affects at least 26 million people worldwide

• Costs US healthcare system estimated $31 billion annually

• Assessment of fluid burden is critical to HF patients

• Current methods of determining fluid levels are either inaccurate or invasive and expensive

• SOZO gives clinicians an objective measure of fluid volume

• More than 20% of HF patients are readmitted within 30 days of hospital discharge

• Ongoing detection of fluid build up is critical to reducing hospital readmissions

• HF Patients with a SOZO HF-Dex reading over 51% at time of discharge are 4.25x more likely to be readmitted[1]

• Recent Advocate Aurora Health contract sets the stage for demonstrating reimbursement and establishing the commercial model

1 Daleiden-Burns A, Accardi AJ, and Heywood JT, Bioimpedance spectroscopy measurement of ongoing fluid overload post-discharge from hospitalization for decompensated heart failure. Journal of the American College of Cardiology 2021. 77(18_Supplement_1):798.

==> picture [853 x 795] intentionally omitted <==

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 14
----- End of picture text -----

==> picture [395 x 92] intentionally omitted <==

Renal Failure Accelerated with FDA Breakthrough Designation

• There are in excess of 450,000 US dialysis patients receiving treatment three times a week

• More than 85% of these treatments will be performed in dialysis centres

• Very attractive concentrated market with two companies caring for 85% of ESRD patients in more than 5,000 dialysis clinics each

• Received FDA Breakthrough Designation for SOZO[®] for a proposed indication in a renal patient population

• Current practice in dialysis clinics rely on scales to determine the amount of fluid to remove

• Scales cannot account for changes in body composition, with muscle loss being prevalent in end-stage renal disease patients

==> picture [729 x 540] intentionally omitted <==

==> picture [275 x 284] intentionally omitted <==

----- Start of picture text -----

Granted August 2021
----- End of picture text -----

• The potential for SOZO to address this deficiency was paramount in meeting the criteria for Breakthrough Designation

• Currently finalising clinical and regulatory strategies

2 international drug studies involving 410+ sites 28 countries evaluating fluid volumes (heart failure & renal failure patients)

in

SOZO technology adopted by AstraZeneca to measure fluid outcomes in heart failure patients with chronic kidney disease

15

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed.

==> picture [395 x 92] intentionally omitted <==

Completion of Expected Milestones from the 2020 AGM

Majority of the goals achieved:

Lymphoedema

• ü Continued strong growth in SOZO[®] SaaS subscription-based business

• ü Meta-analysis published

• ü Publication of additional scientific papers

• Private payors begin coverage of L-Dex — catalyst for broad adoption in US

• ü PREVENT Trial 3-year data published

• ü NCCN Guidelines[®] — Applications for the addition of a formal testing protocol and inclusion of L-Dex

Heart Failure

• ü Commercialisation of SOZO in Heart Failure commences

• ü Heart Failure Paper published and presented

• Regulatory clearance for BIS in HF patients with implantable devices

Renal Failure

• ü Clinical, regulatory and commercial strategy announcements

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

16
----- End of picture text -----

==> picture [361 x 83] intentionally omitted <==

Summary of Focus Areas for 2022 . Continue growth in sales and adoption of SOZO[®] Complete SOZO II development for Heart Failure and Renal Failure indications. Launch software Version 5.0 with data and software enhancements focused on corporate accounts. Publish the PREVENT Trial manuscript in a peer-reviewed journal. Principal Investigators to submit PREVENT data to the NCCN[®] for guideline inclusion. Expand private payor coverage/payment for L-Dex[®] testing. Expand the number of key corporate accounts. Expand commercial sales of heart failure through additional pilot programs in key heart failure centres. Gather real world data on SOZO and reimbursement through HF pilot programs. Continue to work with FDA on obtaining clearance for removal of SOZO contraindications for implantable pacing and cardioverter defibrillators devices. Continued deployment of devices for the AstraZeneca trials, both in the US and internationally. Utilise the FDA Breakthrough Designation to develop regulatory pathway. Announce clinical strategy for Renal Failure. Continue to progress commercial strategy for Renal Failure.

==> picture [1920 x 50] intentionally omitted <==

----- Start of picture text -----

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 17
----- End of picture text -----

==> picture [1920 x 1080] intentionally omitted <==

----- Start of picture text -----

Appendix
----- End of picture text -----

==> picture [361 x 83] intentionally omitted <==

Share Purchase Plan (SPP) – Offer timetable

Event		Date (AEDT)
Record Date Date used to determine Eligible Shareholders		7.00pm on Tuesday, 26 October 2021
Opening Date Offer under SPP opened		9.00am on Wednesday, 3 November 2021
Closing Date Offer under SPP closes		5.00pm on Thursday, 11 November 2021
Allotment Date SPP Shares are issued		Thursday, 18 November 2021
Despatch Date Confirmation of transaction despatched to holders of SPP Shares		Thursday, 18 November 2021
Commencement of normal trading in New Shares issued under the SPP		Friday, 19 November 2021
Key offer details:
Issue Price per Share:	$0.1525 per Share	SPP Documents can be found at:
Maximum application amount:	$30,000	https://www.impedimed.com/about/investors/
Minimum application amount:	$1,000

Refer to the SHARE PURCHASE PLAN issued to the ASX by the Company on 3 November 2021 for full details on the plan. The dates listed are indicative only and ImpediMed retains the right to vary them without advance notice. All references to time are to AEDT.

19

Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed.

==> picture [395 x 92] intentionally omitted <==

==> picture [202 x 253] intentionally omitted <==

Richard Carreon Managing Director and Chief Executive Officer

• Joined July 2012 • 30+ years experience • Extensive experience in the medical device field and growth companies • Previously Vice President at Medtronic (10 years)

Management Team Deep and Broad Commercialisation Experience

==> picture [203 x 247] intentionally omitted <==

==> picture [198 x 249] intentionally omitted <==

Tim Cruickshank Chief Financial Officer • • Joined January 2008 • • 10+ years in financial management in the medical device / • technology industry • Experience in med-tech growth companies with a focus on SaaS modeling and strategy Dennis Schlaht SVP R&D and Technology • Joined October 2007 • 30+ years in engineering development and product marketing • Previously Vice President of Marketing and Product Development at XiTRON’s Test and Measurement Business

Shashi Tripathi Chief Technology Officer

Frank Vicini, MD Chief Medical Officer

• Joined September 2014 • 25+ years as radiation oncologist • Completed his fellowship at Harvard Medical School, has authored over 200 peer reviewed publications, and participated in 6 NIH clinical trials and the MammoSite Registry trial

Joined July 2018 20+ years as a healthcare technology leader Previously SVP of Technology & Operations at New Century Health, where he oversaw all aspects of IT, project and product management, product development and operations

==> picture [203 x 253] intentionally omitted <==

==> picture [203 x 253] intentionally omitted <==

David Adams SVP Operations and Strategic Planning

Nancy Deisinger SVP Human Resources

Joined July 2016 20+ years in human resources, including 10+ years in medical device, working with start-ups to Fortune 500 companies Previously AVP Human Resources at 3E Company

==> picture [7 x 138] intentionally omitted <==

----- Start of picture text -----

•
•
•
----- End of picture text -----

• On Board November 2013 to August 2016 • Joined August 2016 • Background as medical device investment & business development executive • 25+ years experience in tax, financial planning, and business development • Previously Vice President, Integrations and Divestitures at Medtronic

==> picture [203 x 253] intentionally omitted <==

==> picture [210 x 258] intentionally omitted <==

Catherine Kingsford SVP Medical Affairs

• Joined January 2007

• 20+ years global clinical experience with medical devices

• Previously worked as a cardiac scientist at several world-class medical institutions including St. Andrew's War Memorial Hospital, The Prince Charles Hospital, and Royal Brompton Hospital

Michael Bassett SVP Corporate and Strategic Development

• Joined January 2020

• 25+ years experience in capital markets with senior roles at Australia’s leading funds management and investment banking firms

• Previously MD Market Connect, a market consultancy business, Regal Funds Management, Credit Suisse, Deutsche Asset Management and Merrill Lynch

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

==> picture [395 x 92] intentionally omitted <==

Board of Directors

==> picture [202 x 253] intentionally omitted <==

==> picture [207 x 253] intentionally omitted <==

Scott R. Ward Donald A. Williams MS, BSc BAcy, CPA Non-Executive Chairman Non-Executive Director (Retiring) (Incoming Chairman)

• Joined March 2017

• Joined July 2013

• 35+ years in leadership roles serving the life science, biotech, and medical device industries

• Appointed Chairman November 2017

• Retiring November 2021

• Venture capitalist with 35+ years experience in healthcare industry

• Currently the Audit Committee Chair of Akari Therapeutics, Alphatec Holdings, Marina Biotech, and Proove Biosciences, and the Compensation Committee for Marina Biotech

• Currently Chairman, President and CEO of Cardiovascular Systems, Inc.

• Previously Senior Vice President and President of the Cardiovascular business of Medtronic

==> picture [211 x 254] intentionally omitted <==

David Anderson BSc Non-Executive Director

• Joined May 2020

• 20+ years experience as executive in US healthcare industry

• Currently serves as President and CEO of HealthNow Systems Inc, operating as BlueCross BlueShield health plans in New York state

• Previously CEO of United Healthcare’s Southern California Health Plan

==> picture [203 x 253] intentionally omitted <==

Richard Carreon Managing Director and Chief Executive Officer

• Joined July 2012

• • 30+ years experience

• • Extensive experience in the medical device field and growth companies

• • Previously Vice President at Medtronic (10 years)

==> picture [202 x 253] intentionally omitted <==

Judith Downes BA(Hons), DipEd, GradDipBus(Acct), FAICD, FCPA, FCA Non-Executive Director

• Joined April 2017

• 25+ years of accounting and senior management expertise with large ASX listed companies

• Previously a CFO at Alumina Limited and CFO/COO of Institutional Division, ANZ Banking Group Limited

• Currently Board Chairman of Bank Australia Limited, Honorary Fellow of the University of Melbourne’s Faculty of Business and Economics, and Director, CleanTeQ Holdings Limited

==> picture [203 x 254] intentionally omitted <==

Robert M. Graham AO, FAA, FAHMS, MBBS, MD, FRACP, FACP, FAHA Non-Executive Director

• Joined January 2018

• Received medical training at the University of South Wales where he is now the Des Renford Professor of Medicine

• Inaugural Executive Director,

• Victor Chang Cardiac Research Institute, Sydney Australia

• 17+ years experience in US healthcare and currently a consultant physician in cardiovascular diseases

==> picture [202 x 253] intentionally omitted <==

Amit R. Patel MBA, BME Non-Executive Director

• Joined March 2017

• 8+ years in senior management positions across medical device, consumer software, and digital health organisations

• Currently Co-Founder and CEO of Murata Vios, Inc. (formerly Vios Medical, acquired by Murata Manufacturing)

==> picture [1920 x 54] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

==> picture [1221 x 1080] intentionally omitted <==

Contact Details Investor Relations: Mike Bassett SVP Corporate and Strategic Development mbassett@impedimed.com +61 407 431 432 www.impedimed.com